
News|Articles|November 1, 2005
Pipeline Preview
Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Non-approvable designations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
The sleep doctor who lives with a disorder he treats
3
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
4
Rural health is ailing. Is $50 billion enough to heal it?
5













